MIMPARA (cinacalcet), anti-parathyroid agent

Insufficient clinical benefit to justify its reimbursement in the treatment of secondary hyperparathyroidism (HPT) not properly managed with conventional treatments in paediatric dialysis patients > 3 years, with end-stage renal disease

• MIMPARA has MA in the treatment of secondary hyperparathyroidism (HPT) not properly managed with conventional treatments in paediatric dialysis patients > 3 years, with end-stage renal disease.

• There is no significant difference between the combination of cinacalcet with standard treatments and standard treatments alone on the reduction in iPTH.

• There are uncertainties as to the safety of cinacalcet in children, in particular in terms of hypocalcaemia.